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Abstract: In this article we propose a systematic development method for rational drug 
design while reviewing paradigms in industry, emerging techniques and technologies in the 
field. Although the process of drug development today has been accelerated by emergence 
of computational methodologies, it is a herculean challenge requiring exorbitant resources; 
and often fails to yield clinically viable results. The current paradigm of target based drug 
design  is  often  misguided  and  tends  to  yield  compounds  that  have  poor  absorption, 
distribution,  metabolism, and  excretion,  toxicology (ADMET)  properties. Therefore, an  
in vivo organism based approach allowing for a multidisciplinary inquiry into potent and 
selective molecules is an excellent place to begin rational drug design. We will review how 
organisms like the zebrafish and Caenorhabditis elegans can not only be starting points, 
but can be used at various steps of the drug development process from target identification 
to pre-clinical trial models. This systems biology based approach paired with the power of 
computational  biology;  genetics  and  developmental  biology  provide  a  methodological 
framework to avoid the pitfalls of traditional target based drug design.  
Keywords:  phenotypic  screen;  drug  discovery;  small  molecules;  drug  design  chemical 
genetics; model organisms 
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1. Introduction  
Cancer, Alzheimer, diabetes; all are leading causes of death in the US. Unlike exogenous factors 
like HIV/AIDS and influenza, they are the result of endogenous developmental programming behaving 
in an aberrant fashion. As the average lifespan of human increases, certain biological machineries in 
our bodies start to break down. Even if all exogenous infections were obliterated from the face of the 
globe we would still face these diseases. Pharmaceutical companies face the challenge of modulating 
these developmental processes with small molecules. The human genome consists of approximately 
25,000 genes [1]. Of these genes only 3000 of which are thought to be druggable and 50% of those 
thought to be disease causing [2]. A list of ~1500 potentially druggable disease causing biomolecules 
is  now  the  center  of  focus  in  the  pharmaceutical  industry.  The  current  paradigm  of  drug  design 
revolves  around  these  biomolecule  targets  and  designing  and  identifying  small  molecules  that 
modulate  the  activity  of  them  in  vitro  or  in  silico;  this  is  called  a  “target  centered”  approach  
(Figure 1a). Let us look at the track record of this approach. Only 1 of 5000 discoveries makes it to 
market from the bench side. The average time it takes a drug to reach the bedside from discovery is 12 
years,  and  a  single  pharmaceutical  agent  costs  from  500  million  to  2  billion  dollars  to  bring  to  
market [3]. How could all but one of 5000 discoveries end up being useless as a therapeutic? The 
answer may lie in the “target centered” paradigm that has driven drug design for the past 50 years.  
Figure  1.  Workflow  for  two  paradigms  of  drug  discovery.  (A)  Conventional  “Target 
centered” drug discovery; (B) In vivo model based drug discovery. 
 
This  paradigm  is  not  without its  successes.  The  anti-hypertensive agent  Captopril  produced  by 
Bristol  Meyer-Squibb  is  a  potent  and  reversible  inhibitor  of  Angiotensin-converting  enzyme. Int. J. Mol. Sci. 2011, 12                       
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Approved by the FDA in 1981 it rapidly became an effective treatment for hypertension and heart 
failure [4]. And Novartis produced an FDA approved drug Aliskiren, in 2007 with a combination of  
X-ray crystallography and computer aided design [5]. However, most of these target centric designs 
often  fail  to  meet  the  standard  when  ADMET  (absorption,  digestion,  metabolism  and  toxicity)  is 
evaluated after years of research and millions of dollars. In place of this paradigm, a systems biology 
approach is emerging using a phenotypic screen that inherently takes into account certain ADMET 
properties. The following article will present a systematized development method for rational drug 
design based on phenotype driven discovery.  
2. Workflow 
The first step in  in vivo phenotypic discovery is the defining the desired phenotype of a “hit” 
compound. Currently, there are two major types of phenotypic screens. First is a forward chemical 
genetic screen, which consists of inducing a desired phenotype in a wild typesetting in your model 
organism (Figure 1B). The second is a therapeutic screen, taking a disease model and reversing it with 
a compound. However, before either screen can be done a decision must be made about which model 
system to use. There is also an emerging third type of screen, known as a pathway screen. This screen 
looks for a change in a particular signaling pathway in vivo. The second decision that must be made is 
which model will be used for the screen. The model organisms are, namely, Drosophila, C. elegans, 
zebrafish, or stem cells, which are all discussed below and summarized (Table 1). Further, strategies to 
identify the molecular target of the hit ligand must be considered; since a compound with completely 
unknown mechanism of action is unlikely to gain ready acceptance. Various techniques for target 
identification exist and are not mutually exclusive. Broadly, they are transcriptome profiling, affinity 
pull down, affinity response target screening, and yeast 3 hybrid screening. At this juncture, it is 
important to consider whether a “hit” compound is bioactive in live animals, depending on what model 
was used for initial screening. Assuming the ultimate goal of a chemical screen is to discover novel 
therapeutics for humans, it would be important to test whether the small molecule intervention robustly 
elicits desired effects without toxicities in inexpensive model organisms, prior to advancing the small 
molecule toward much more expensive clinical testing. Indeed, it has been estimated that just 10% 
improvements in predicting failures before clinical trials could save $100 million per drug [6].  
Table 1. Comparison of in vivo small molecule discovery models.  
  C. elegans  D. melanogaster  D. rerio  M. musculus 
Generation Time  3–5 days  10–14 days  3–4 months  6–8 weeks 
Media  Solid or liquid  Solid  Liquid  N/A 
Ease of Obtaining Embryos   +++++  +++++  ++++  N/A 
Number of Genes  ~19,000  ~13,000  ~25,000  ~25,000 
Homology to Human Genome  >50%  >60%  >70%  >90% 
Annual Cost  +  +  ++  ++++ 
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3. Organismal Models 
Invertebrates are small, low cost and tend to have high fecundity; as such, they are one possible 
avenue  for  screening  models.  One  such  invertebrate  worming  its  way  into  drug  discovery  is 
C. elegans; it is a nematode with a short life cycle (approximately 3.5 days) and can be raised in liquid 
media  while  consuming  E.  coli.  Each  adult  hermaphrodite  consists  of  959  cells  and  can  produce  
~300 larvae by self-fertilization. Since it started being used by Sydney Brenner in 1960s [7], it has 
been  used  to  study  cancer  [8],  neuronal  cell  death  [9],  and  cilia  [10].  C.  elegans  has  also  been 
established  as  a  disease  model  of  Alzheimer’s  disease  [11],  Parkinson’s  disease  [12],  Friedrich  
ataxia [13], and diabetes mellitus [14]. Recently the small nematode has made progress as a screening 
tool,  in  part  due  to  a  HTS  method  of  arraying  larvae  [15].  For  example,  Kwok  and  colleagues 
identified  a  novel  calcium  antagonist  that  targets  egl-19,  the  L-type  calcium  channel  
alpha1-subunit [16]. Additionally, an automated image analysis based high-throughput screen utilizing 
transgenic  worms  identified  known  autophagy  enhancers  that  could  be  used  to  treat  human  liver 
diseases caused by protein misfolding [17]. Despite the versatility of C. elegans as a screening model, 
it has a few important drawbacks. First, its homology to the human genome is relatively low, with 
approximately 50% of human genes having orthologues [18]. Many organs in the human body do not 
have corresponding structures in C. elegans. The C. elegans body is also covered by a thick cuticle that 
is hard to penetrate [19]. Many compounds will not penetrate it unless a special solvent containing 
naphthalene and para-dichlorobenzene is added to the media [20]. Overall, C. elegans is promising 
model for in vivo small molecule screening to yield tools for simple biologically conserved pathways. 
Table 2. Summary of types of phenotypic screens in zebrafish.  
Embryo  Type of Screen  Readout 
 
 
 
Wild type 
 
 
 
Chemical genetic 
 
 
 
Morphological defect 
 
 
Disease model 
(eg. Blood pooling) 
 
 
 
Therapeutic 
 
 
 
Restored to wild type 
 
 
Trangenic Embryo 
Tg(Flk:dsRed)  
 
 
 
Transgene assisted 
 
 
Altered anatomy visualized 
through transgenic marker 
 
 
 
Transgenic Reporter Line 
Tg(Top:dGFP) 
 
 
 
Pathway Reporter  
inhibitor /enhancer 
 
 
 
 
Down regulated Reporter gene 
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Another invertebrate that shows potential for small molecule screening is the fruit fly Drosophila 
melanogaster. It has been used for over a century in genetics research. Drosophila is anatomically 
more  similar  to  mammals  and  has  more  than  60%  genomic  homology  to  humans  [21].  As  with 
C. elegans there are many mutants and even a fair number of disease models ranging from muscular  
dystrophy [22], to Alzheimers [23]. Recently this model has successfully been used by Chang and 
colleagues in a therapeutic screen. Briefly, a screen of 2000 compounds resulted in identification of 
nine molecules that rescue the Drosophila model of fragile X syndrome [24]. This screen, in addition 
to  providing  new  small  molecule  tools,  uncovered  a  novel  function  for  muscarinic  cholinergic 
receptors acting in parallel to the GABAergic pathway in rescuing fragile X syndrome phenotypes. 
Despite these impressive results, the drawbacks of using Drosophila as a small molecule screening 
model are three-fold. First, the organism is covered with a cuticle that is hard to penetrate. Secondly, 
Drosophila does not grow in a liquid media so precise dosing of small molecules in a high throughput 
manner  is  difficult.  Thirdly,  as  with  C.  elegans,  the  Drosophila  model  lacks  some  anatomical  
(e.g., closed circulatory system) and genetic components that are present in humans. 
As a vertebrate model of human disease, mouse has long been the gold standard. However, the size, 
labor  and  time  requirements  for  mice  make  them  cost  prohibitive  for  conducting  small  molecule 
screens. However, there has been some limited success in chemical screening using mice. A proof of 
principle comparison of anti-TB drugs has been conducted and shows promise as a methodology for 
conduction large scale screens for TB therapeutics [25]. In recent years, another vertebrate model has 
emerged at the forefront of small molecule screening. Over the past 20 years the zebrafish has made a 
substantial  impact  in  biological  research.  It  has  been  used  to  study  multiple  areas  ranging  from 
vascular development [26,27] and neural development [28], to disease models for cancer [29] and 
melanocyte  development  [30].  The  embryos  are  roughly  1  mm  in  size  and  3–6  embryos  can 
comfortably be arrayed in the wells of a 96-well plate [31]. Its size, low cost, and fecundity make 
zebrafish an attractive model for basic research. In addition, the liquid media, genetic homology to 
humans (over 70%), and rapid development of most organs within 48 h post fertilization, make it an 
ideal model for small molecule screening. With these advantages, the small teleost is swimming its 
way into the field of chemical genetics. There are four major models for phenotypic screening in 
zebrafish;  they  are  chemical  genetic,  therapeutic,  transgene  assisted  and  pathway  based  screens  
(Table 2). We have, in a chemical genetic screen, used perturbation of dorso-ventral (front to back) 
polarity in zebrafish embryos to discover dorsomorphin, the first selective Bone morphogenic protein 
(BMP) type I receptor [32]. Dorso-ventral patterning in zebrafish is established primarily through a 
functional antagonism between Wnt and BMP, but perturbations in numerous other pathways can distort 
the overall embryonic patterning. In a slightly more focused, transgene assisted, approach screening 
for anti-angiogenic agents, transgenic fish expressing GFP under a vasculature specific promoter were 
used in an automated and quantitative screen. This identified two known anti-angiogenic agents along 
with one other novel compound [33]. Zebrafish have also been used to screen for modifiers of specific 
pathways such as Fgf through the use of a florescent reporter [34].  
In addition to organism based phenotypic screens, chemical screen using pluripotent stem cells has 
emerged as a viable alternative. A major benefit of screening in human derived stem cells is that one 
doesn’t need to worry about translatability in terms of conservation and orthology. Stem cells are 
grown  in  liquid  media  and  can  be  arrayed  in  a  96-well  format  to  form  uniform  sized  embryoid Int. J. Mol. Sci. 2011, 12                       
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bodies [35]. Stem cells can give rise to all three germ layers and any cell type should be derived. Small 
molecules have successfully been used to create numerous cell types including cardiomyocytes [36,37]. 
Because of this attractive therapeutic potential, for directed differentiation, a small molecule screens 
using stem cells (R1 cells) was conducted by Zhu and colleagues for small molecules that promoted 
differentiation into definitive endoderm by assaying for expression of a sox17-rfp [38]. Additionally, 
ectoderm derived neurospheres were also used for assay for neurogenic compounds in a phenotypic 
screen [39]. However, as with many cell based assays this model for phenotypic screening could also 
potentially lead to identification of compounds that have poor ADME properties. This methodology 
could be applied to the generation of any number of cell types for which specific markers are available, 
such as Beta-cells and could substantially help the field of regenerative medicine.  
Table 3. Overview of molecular target identification technologies. 
Strategy  Advantages  Disadvantages 
Affinity 
Chromatography 
Traditionally used and readily accepted  Requires sophisticated equipment 
Low throughput 
Requires chemical modification 
Expression Profiling  No chemical modifications 
High throughput 
Data can be noisy 
Requires sophisticated bioinformatics 
Imprecise 
Yeast 3 Hybrid  High throughput  Non native environment 
Not suitable for membrane bound proteins 
Requires chemical modifications 
DARTS  No chemical modifications 
Does not require high affinity 
Low throughput 
4. Target Identification 
Traditional drug design starts with the identification of a possible therapeutic target. For phenotypic 
screens target identification is the bottle neck for drug development. However, major advances are 
being  made  in  the  field  for  more  efficient  and  rapid  identification.  These  techniques  can  for  our 
purposes be broken into two broad categories; techniques requiring modification of the small molecule 
and techniques that can use the native molecule. 
The first two methods, that don’t require modification of the ligand, are based on comparative 
transcriptome profiling. By utilizing a network systems biology approach one can identify the central 
nodes of affected gene clusters. This can yield a broad view of the mechanism of action [40]. One can 
also  use  hierarchical  clustering  which  has  been  successful  in  both  yeast  and  rat  tissue  [41].  This 
however provides documentable cell-type specific effects, and also microarray specific effects. An 
alternative approach is through the use of the Connectivity Map [42]. This takes a rank based pattern 
matching strategy applied to a database of over 7000 expression profiles representing 1309 compounds 
to identify similarities and thus potential target pathways [43].The problem with the listed techniques 
thus far, has been that they are unable to pinpoint specific binding partners. There is a new technique 
called  Drug  Affinity  Response  Target  Screening  (DARTS)  [44].  When  a  small  molecule  binds  a 
molecule there is a physical response. This response can be proteolytically protective, and the resultant Int. J. Mol. Sci. 2011, 12                       
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protected peptide sequence can yield the target protein. The efficacy of this method has been tested 
with both high and low binding affinity molecules. This technique does not depend on an in vivo 
response and gives large amount of flexibility. 
If one has a good understanding of the structure activity relationship for the compound and the 
phenotype one can alter the small molecule so it can be affixed to a linker. Once a linker is affixed to 
the small molecule, there are two approaches that can be taken. The first is the chemical proteomic 
approach; this approach is based on affinity chromatography and utilizes the pull down of candidate 
proteins.  This  has  been  the  golden  standard  in  the  field  for  many  years.  With  advances  in  MS 
technology and protein technologies there are new flavors of this approach that use isotope labeled 
proteins (a significant review of these methods was written by Rix and Superti-Furga [45]). Another 
technique that can be used is a variation of the yeast two hybrid screen. The yeast 3 hybrid screen 
requires the small molecule to be linked to a methotrexate moiety (the anchor). This molecule will 
attach itself to the hybrid dihydrofolate reductase-LexA DNA binding domain via the methotrexate. 
The small molecule bait will bring any target molecules (from a cDNA library of Gal4 activation 
domain fusions) within range of the DNA binding domain to elicit a His-3 reporter [46].
 This is a 
versatile system and the cDNA libraries are commercially available from a number of sources for a 
number of different model systems.  
5. SAR and Compound Optimization 
Most SAR studies are done with a priori knowledge of the target molecule or pathway. Recent 
advances  in  computer  technology  have  made  molecular  modeling  based  on  crystallized  protein 
structure feasible for even small laboratories [47]. Traditionally, an in vitro assay is used for testing 
analogs to determine SAR. However, it is possible to conduct SAR in vivo using a phenotypic model 
as  a  read  out.  Hao  and  colleagues  used  the  zebrafish  model  to  perform  the  first  in  vivo  SAR  of 
dorsomorphin  analogues.  With  this  system  they  were  able  to  derive  compounds  with  differing 
specificities for Vegf and Bmp receptors [48]. Although the target for dorsomorphin was known, this 
new paradigm of in vivo SAR could be used prior to any knowledge of target pathways as it only 
requires a simple read-out. This in vivo approach also helps in identifying not just the most potent 
forms of the compound; but also takes into account the in vivo permeability of the compound. 
6. Vertebrate Toxicity 
One of the major reasons potential drugs fail before they reach the market is because of the off 
target effects that manifest during clinical trials. The International Conference on Harmonization (ICH) 
S7A guidelines state that prior to clinical trial in humans, that pharmacophores must be evaluate on the 
vital functions, namely the circulatory system, CNS, G.I., and skeletal systems [49]. Of the models 
discussed  above,  only  the  zebrafish  and  mouse  have  all  these  systems  (Figure  2).  Traditionally, 
toxicological data is obtained from mouse. This is however, as mentioned before, a costly model 
system.  In  recent  years  zebrafish  have  emerged  as  a  viable,  low  cost  alternative  for  determining 
compound affects on these major organ systems and could be a useful tool for identifying liabilities of 
pharmacophores during early stages of drug development. 
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Figure 2. Conservation of organ systems between zebrafish and humans. The zebrafish is a 
versatile model that is useful not only drug discovery but rapid development of organ 
systems makes it ideal for assessing biochemical safety and toxicity 
 
The zebrafish circulatory system forms and is functional by 23 h post fertilization (hpf), and by 
48 hpf the heart has undergone looping to form a distinct atrium and ventricle. The transparency of the 
zebrafish embryo allows for easy visualization of both the heart and blood circulation. A screen was 
done with 23 drugs known to cause QT prolongation and torsades de pointes in man, to identify if 
zebrafish would phenocopy the results in 3 days post fertilization (dpf) zebrafish embryos. The results 
identified 18 that caused brachycardia [50]. Furthermore, a transgenic line that expresses GFP under a 
cardiac specific promoter has been developed and an automated method of determining heart rate in a 
high throughput manner has been developed [51]. For further cardiovascular effects, zebrafish blood 
can  be  visualized  for  hemorrhages  and  an  image  capture  analysis  of  single  erythrocytes  can  be 
conducted to assess the contractility of the heart [52]. Within the first 48 h post fertilization zebrafish 
develop a touch response, at 68 hpf they have a visual startle response, are capable of free swimming 
at 96 hpf, and develop an auditory startle response by 5 dpf. Screens have been conducted on all of 
these nervous system responses and have shown remarkable predictability of identifying problems also 
caused in humans [53–56]. For example, in a study of 8 compounds that can cause visual impairment 
in man, 6 inhibited the optokinetic motor response correctly in zebrafish [57]. At 36 hpf the zebrafish 
digestive tract begins to form, and it becomes fully functional and zebrafish are fed exogenously by 
5 dpf [58]. As with blood cells, the optical clarity of the zebrafish allows for easy visualization of the 
peristaltic contractions of the intestine. In a study of compound effects on gut mobility 8 of 10 compounds 
showed corresponding decreased contractility in zebrafish [58]. Finally, as a vertebrate the zebrafish 
model allows one to assess bone mineralization by 10 dpf. This is a proof of principle as the study was 
conducted with prednisolone which substantially decreased bone mineralization in zebrafish [59]. The 
flexibility and anatomical conservation between man and zebrafish make it ideal for assessing toxicity 
of various organ systems.  Int. J. Mol. Sci. 2011, 12                       
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7. Afterword 
Rational drug design has traditionally depended on a thorough understanding of the disease to be 
treated so a target protein can be selected and ligands can be screened against that molecular target. 
However,  many  diseases  are  complex,  and  regardless  of  the  progress  made  in  understanding  the 
disease  a  coherent  model  cannot  be  established.  This  is  particularly  true  for  psychological  and 
neurological  diseases  such  as  Alzheimer’s  and  Parkinson’s  disease.  In  the  treatment  of  many 
psychological  disorders  the  only  pharmaceuticals  available  target  serotonin,  dopamine,  or 
norepinephrine signaling. These diseases are diagnosed based on behavior; therefore a model with 
quantifiable behaviors is necessary for in vivo screening. Recently, a screen for chemical modulators of 
wake/rest cycle was conducted using zebrafish [60]. This study implicated a novel pathway involving 
ERG (ether-a-go-go) potassium channel proteins. Another potential avenue for in vivo screening is 
cancer. Zebrafish can be injected with human cancer cells at 2 dpf and assessed for both angiogenic 
response  (1  day  post  implantation)  and  metastatic  behavior  (5  days  post  implantation)  [61]. 
Conducting a small molecule screen on these fish could yield novel therapeutics that target the cancer 
cells specifically in an in vivo environment. Furthermore different cancer cell lines respond differently 
and as such this screen could be conducted on different lines of cancer cells and yield different results. 
Whether a disease is well understood or not, phenotypic screens using in vivo small animal models like 
the zebrafish show great promise for aiding drug discovery and development at many steps of the drug 
development process.  
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